Why is Syngene International Ltd falling/rising?

Recent Price Movement and Market Context

On 20 January, Syngene International Ltd closed at ₹606.00, down ₹19.80 or 3.16% from the previous session. This decline continues a five-day losing streak, during which the stock has dropped approximately 4.44%. The share price is now perilously close to its 52-week low of ₹598.55, just 1.23% above that level, signalling sustained selling pressure. Intraday trading saw the stock dip to ₹602.90, marking a 3.66% fall on the day, with heavier volumes concentrated near these lower price points, indicating bearish sentiment among traders.

The stock’s underperformance is also evident when compared to its sector and benchmark indices. Syngene has lagged the Pharmaceuticals & Drugs sector, which itself declined by 2.1% on the same day, with the stock underperforming the sector by over 1%. Over the past week and month, Syngene’s returns of -3.90% and -7.37% respectively have been significantly worse than the Sensex’s corresponding declines of -1.73% and -3.24%. Year-to-date, the stock has fallen 6.90%, nearly double the Sensex’s 3.57% drop. Over the last year, the stock’s performance has been particularly poor, plunging 26.21% while the Sensex gained 6.63%. This stark contrast underscores the stock’s relative weakness amid broader market gains.

Technical Indicators and Investor Participation

Technically, Syngene is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a sustained downtrend. This technical weakness is compounded by a sharp decline in investor participation; delivery volumes on 19 January fell by 67.62% compared to the five-day average, suggesting waning interest from buyers. Despite this, liquidity remains adequate, with the stock able to support trades worth approximately ₹0.58 crore based on 2% of the five-day average traded value.

Fundamental Challenges Weighing on the Stock

Syngene’s recent financial disclosures have done little to inspire confidence. The company reported a significant 47.1% drop in quarterly profit after tax (PAT) to ₹67.10 crore compared to the previous four-quarter average. Operating profit margins have also contracted, with the operating profit to interest coverage ratio at a low 15.11 times and quarterly PBDIT falling to ₹199.50 crore, the lowest in recent periods. These results highlight operational pressures and margin compression that have unsettled investors.

Long-term growth metrics further dampen enthusiasm. Over the past five years, net sales have grown at a modest annual rate of 12.63%, while operating profit has expanded by just 9.01% annually. Such growth rates are underwhelming relative to sector peers and broader market expectations. The company’s return on equity (ROE) stands at 9.9%, which, when combined with a high price-to-book value of 5.2, suggests the stock is trading at a premium valuation despite its subdued growth and profitability.

Moreover, the price-to-earnings-to-growth (PEG) ratio is an alarming 35.6, signalling that the stock’s price far exceeds what its earnings growth justifies. This disconnect between valuation and fundamentals has likely contributed to the sustained selling pressure. Over the past year, while profits have inched up by a mere 1.6%, the stock has lost over a quarter of its value, reflecting investor scepticism about the company’s growth prospects and valuation.

Comparative Performance and Institutional Holding

Syngene’s underperformance is not limited to the short term. Over three and five years, the stock has lagged the BSE500 and Sensex indices, which have delivered robust returns of 35.56% and 65.05% respectively over five years, compared to Syngene’s marginal gains or slight losses. This persistent lag highlights structural challenges in the company’s growth trajectory and market positioning.

On a positive note, Syngene maintains a low debt-to-equity ratio, effectively zero, which reduces financial risk. Institutional investors hold a significant 40.8% stake, indicating that well-informed market participants continue to back the company, albeit cautiously. However, this has not translated into price support amid the prevailing negative sentiment.

Conclusion: Why Syngene International Ltd Is Falling

In summary, Syngene International Ltd’s recent share price decline is driven by a combination of weak quarterly financial results, disappointing long-term growth rates, and a valuation that appears stretched relative to its earnings and book value. The stock’s persistent underperformance against benchmark indices and sector peers further exacerbates investor concerns. Technical indicators confirm a bearish trend, while reduced investor participation signals a lack of conviction among buyers. Although the company benefits from low leverage and strong institutional ownership, these positives have not been sufficient to offset the negative sentiment.

Investors should carefully weigh these factors when considering Syngene’s stock, as the current market environment and fundamental challenges suggest continued pressure on the share price in the near term.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →